GlassScriptPhysician profile
John Thomas Paulsel
NPI 1285611764
$1,712.03
in general payments reported to CMS, 2019-2025
24 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $68.97 · 2022: $41.66 · 2023: $696 · 2024: $311 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.82 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $311.96 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $307.40 | 2023-2025 | |
| Astellas Pharma US INC | $142.75 | 2019-2023 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $136.82 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $118.45 | 2023-2024 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Lilly USA, LLC | $117.75 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $109.46 | 2023-2025 | |
| Pfizer INC. | $56.31 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $52.77 | 2019 | |
| Radius Health, INC. | $44.50 | 2024-2025 | Tymlos |
| Idorsia Pharmaceuticals US INC | $43.04 | 2023-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $40.64 | 2025 | Edarbi, Alvesco |
| Amgen INC. | $32.19 | 2020-2025 | Evenity |
| Allergan, INC. | $26.35 | 2020 | |
| Recordati_rare_diseases_inc. | $25.68 | 2025 | Isturisa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.48 | 2023 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $22.83 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $16.84 | 2025 | Unithroid |
| Esperion Therapeutics, INC. | $15.16 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $14.10 | 2024 | Livalo |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2019 | |
| Amarin Pharma, INC. | $13.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paulsel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.